ProCE Banner Activity

Optimizing MRD Assessment in ALL: Why, How, and When

Clinical Thought
Clinical data on MRD assessment in ALL is accumulating, but should you be using it in your practice?

Released: April 22, 2016

Expiration: April 21, 2017

Share

Faculty

Dan Douer

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.

Faculty Disclosure

Primary Author

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

Dan Douer, MD, has disclosed that he has received consulting fees from Amgen, Baxalta, Gilead Sciences, Jazz, Pfizer, and Spectrum; fees for non-CME/CE services from Baxalta and Jazz; and funds for research support from Baxalta, Bristol-Myers Squibb, Gilead Sciences, and Jazz.